Q-linea AB (publ) (OMX: QLINEA) today announces it will provide ASTar® to Italian users of the Accelerate Pheno rapid AST system
Q-linea announces that its ASTar, a system for rapid antimicrobial susceptibility testing (rAST), has been chosen to fulfill tender obligations at several Italian laboratories, following the withdrawal of the Accelerate Pheno system from the market.
Franco Pellegrini, VP Sales EMEA at Q-linea, comments:
“We are working closely with the laboratories affected by Pheno’s discontinuation to ensure a smooth and immediate transition to ASTar as their new rAST solution of choice. Customers have selected ASTar for its ease of use, broad organism and antibiotic coverage, and high-throughput capabilities. In addition to these projects, we are actively evaluating further requests from current Pheno users seeking a reliable replacement for their rAST needs.”